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Tao Cheng1,2,7,9,10* and Xiao-Bing Zhang1,2,3*
Abstract
Background: Hemophilia A, a bleeding disorder resulting from F8 mutations, can only be cured by gene therapy. A
promising strategy is CRISPR-Cas9-mediated precise insertion of F8 in hepatocytes at highly expressed gene loci,
such as albumin (Alb). Unfortunately, the precise in vivo integration efficiency of a long insert is very low (~ 0.1%).
Results: We report that the use of a double-cut donor leads to a 10- to 20-fold increase in liver editing efficiency,
thereby completely reconstituting serum F8 activity in a mouse model of hemophilia A after hydrodynamic
injection of Cas9-sgAlb and B domain-deleted (BDD) F8 donor plasmids. We find that the integration of a double-
cut donor at the Alb locus in mouse liver is mainly through non-homologous end joining (NHEJ)-mediated knock-
in. We then target BDDF8 to multiple sites on introns 11 and 13 and find that NHEJ-mediated insertion of BDDF8
restores hemostasis. Finally, using 3 AAV8 vectors to deliver genome editing components, including Cas9, sgRNA,
and BDDF8 donor, we observe the same therapeutic effects. A follow-up of 100 mice over 1 year shows no adverse
effects.
Conclusions: These findings lay the foundation for curing hemophilia A by NHEJ knock-in of BDDF8 at Alb introns
after AAV-mediated delivery of editing components.
Keywords: Hemophilia A, CRISPR-Cas9, Genome editing, Knock-in, NHEJ
Background
Hemophilia A (HA) is one of the most common genetic
disorders, with an incidence of 1 in 5000 male births in
the USA, representing ~ 85% of all hemophilia cases [1].
HA is caused by mutations in the blood coagulation fac-
tor VIII (F8) gene on chromosome X. Recombinant F8
has been widely used to treat HA, but this has led to the
induction of inhibitory antibodies in 20–30% of patients
[2], limiting the efficacy of the treatment.
Significant progress has been made in treating
hemophilia B (induced by F9 mutations) by adeno-
associated virus (AAV)-based gene therapy due to the
short length of the F9 protein (461 amino acids long).
Infusion of AAV vectors expressing factor IX Padua
(F9–R338L) has achieved sustained expression of active
F9 protein [3]. Due to the packaging limit of AAV, how-
ever, the progress of hemophilia A gene therapy is lag-
ging. The entire F8 protein is 2332 amino acids long [4],
but the deletion of a large portion of the B domain de-
creases the size by 38% [5]. As such, investigators have
used B domain-deleted F8 (BDDF8) in gene therapy
studies. After injection of high-dose BDDF8-encoding
AAV5 and careful management of immune reaction to
AAV by prednisolone administration, multiple adult pa-
tients achieved relatively stable serum F8 activity for up
to 1 year [6]. Despite the promising outcome, long-term
safety and efficacy remain to be determined [6] since
hepatocyte turnover will lead to a gradual loss of AAV,
albeit at a slow pace in adults. Re-administering the
same vector is challenging as a result of AAV-
neutralizing antibodies elicited by the initial treatment.
For the same reason, non-integrating AAV therapy does
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not apply to pediatric patients. Here, we attempt to de-
velop a therapy that may benefit patients of all ages
using a genome editing approach.
Genome editing tools, such as zinc finger nuclease
(ZFN) [7–9] and CRISPR-Cas9 [10–13], have been used
for treating hemophilia B in mouse models. After
dsDNA cleavage, a homology-directed repair (HDR)
donor guides the targeted insertion of the promoterless
vector at intron 1 or exon 2 of F9, leading to its expres-
sion. Thus far, there has been no report of successful
HA treatment using CRISPR-Cas9, primarily due to the
large size of the BDDF8 gene (4.4 kb) compared to the
F9 gene (1.4 kb). Recently, we reported a five- to tenfold
increase in precise gene knock-in using a double-cut
donor vector design, in which Cas9-sgRNA induces sim-
ultaneous genomic DNA (gDNA) cleavage and release of
a linearized HDR template [14]. We hypothesized that
this approach would also increase the insertion efficiency
of a large DNA fragment in vivo.
The liver is the preferable target organ for in vivo gen-
ome editing because hepatocytes can be efficiently trans-
fected by AAV after intravenous injection or by naked
plasmids after hydrodynamic injection [15, 16]. Gene
targeting to the liver offers another advantage by indu-
cing immune tolerance to vectors like AAV and thera-
peutic factors [17]. Since it is endothelial cells rather
than hepatocytes [18] that mostly express F8, the in situ
correction of F8 in hepatocytes is not a viable thera-
peutic option. Instead, we attempted to target BDDF8 at
the albumin (Alb) locus, a highly expressed gene in he-
patocytes [9, 19].
In this study, we report that the double-cut donor de-
sign leads to the integration of BDDF8 in 1–2% of liver
cells at Alb after hydrodynamic injection of plasmids en-
coding Cas9, sgAlb, and pDonor. As a result, we effectively
corrected hemophilia A in most of the affected mice. We
also delivered genome editing components into hepato-
cytes by intravenous injection of AAV8 vectors and found
that multiple sites on Alb introns can be harnessed for
non-homologous end joining (NHEJ) insertion of the
BDDF8 donor. This approach may be further developed
into a clinical therapy for curing hemophilia A.
Results
High knock-in efficiency at Alb with a double-cut donor
We have recently reported that the use of a double-cut
donor leads to a 5- to 10-fold increase in knock-in effi-
ciency relative to circular plasmid donors [14]. Almost
all the editing events in human pluripotent stem cells
are HDR when homology arms of 300–600 bp are used.
The double-cut donor is an HDR template flanked by
single-guide RNA (sgRNA)-PAM sequences and is re-
leased after Cas9-sgRNA cleavage. Encouraged by this
result, we attempted to use the same approach for
in vivo genome editing of HA mice. We used a mouse
model of hemophilia A, induced by targeted deletion of
exon 16 of the F8 gene [20].
Similar to previous studies [19], we decided to target
BDDF8 to the fragment surrounding the Alb stop codon
for high-level expression of the therapeutic factor. We
used the plasmids pEF1-Cas9, whereby the EF1 pro-
moter drives Cas9 expression, and pU6-sgAlb, whereby
the U6 promoter drives the expression of an sgRNA tar-
geting Alb (Additional file 1: Figure S1A). We first ex-
amined the cleavage efficiency by hydrodynamic tail-vein
injection of CRISPR plasmids to the liver in adult mice
(Fig. 1a) [16]. PCR amplification of the target site
followed by deep sequencing 1 week after injection indi-
cated indel efficiencies of 2–6% (Additional file 1: Figure
S1B, C).
We then designed HDR donors in hopes to precisely
insert BDDF8 at Alb. To facilitate the analysis of gene-
edited cells, we designed the target vector to insert both
a tdTomato and BDDF8 coding sequence, linked by an
E2A peptide derived from the equine rhinitis A virus
(E2A) [21] (Fig. 1b), allowing the production of multiple
proteins from a single reading frame by ribosomal skip-
ping [21]. After editing, the tdTomato and BDDF8 ex-
pression cassette replaces the Alb stop codon, and the
endogenous Alb transcriptional machinery drives the
equimolar expression of Alb, tdTomato, and BDDF8.
We then compared pD-tdTomato-BDDF8 (pDonor), a
conventional circular HDR donor, to pD-tdTomato-
BDDF8-sg (pDonor-sg), a double-cut donor (Fig. 1c).
The proportion of tdTomato+ cells in the liver 1 week
after hydrodynamic injections represents the knock-in
efficiencies. The pDonor-sg strikingly increased knock-in
efficiency from ~ 0.1 to ~ 2% (~ 16-fold increase; Fig. 1c).
As expected, the omission of sgRNA and/or Cas9 led to
0% tdTomato+ cells, suggesting that only precise inser-
tion of the promoterless template leads to positive sig-
nals by FACS analysis (Fig. 1d).
After HDR integration, the Alb transcriptional ma-
chinery will drive the expression of Alb, tdTomato, and
BDDF8. As expected, the F8 coagulant activity in treated
HA mice mirrored the results of tdTomato+ cells, and
the double-cut donor design increased F8 activity from
13 to 134% of normal levels in the plasma (Fig. 1e). We
further confirmed the expression of tdTomato in edited
hepatocytes by confocal imaging (Fig. 1f) and 3D recon-
stitution (Additional file 2: Video S1).
We also compared the pDonor vs. pDonor-sg template
by targeting mNeonGreen, a bright green fluorescent
protein, at Alb. We observed a 24-fold increase in the
proportion of mNeonGreen+ cells 1 week after hydro-
dynamic injection when using the double-cut pDonor-sg
compared to the conventional HDR pDonor plasmid
(5.94% vs. 0.24%; Additional file 1: Figure S2).
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Together, our double-cut donor vector design leads to
a complete reconstitution of F8 coagulant activity 1 week
after hydrodynamic injection of editing plasmids in HA
mice.
BDDF8 knock-in at Alb stop codon is mediated by both
NHEJ and HDR
It is also possible that the double-cut donor could insert
at a target site through NHEJ directly [22]. To investi-
gate the proportion of knock-in contributed by HDR vs.
NHEJ, we amplified the left and right junctions using
PCR. One primer is located at BDDF8 or PolyA and an-
other at the outside of the homology arm (Fig. 2a). In
this experiment, we did not include the marker gene
tdTomato in the donor for simplicity. As expected, after
injection of Cas9, sgRNA, or pDonor plasmid alone, the
HA mice showed only baseline levels of F8 activity (~ 5%
of normal serum levels).
Similarly to the study using the tdTomato-BDDF8
donor, the injection of all the editing vectors led to
115% F8 activity (Fig. 2b). After harvesting gDNA from
the liver for PCR analysis 1 week after treatment, we
observed donor integration by both HDR and NHEJ in all
five mice. The band sizes for the left and right junctions
are expected to be 864 bp and 835 bp for HDR knock-in
and 1496 bp and 1421 bp for NHEJ-mediated insertion
due to the presence of an extra copy of the homology arm
of ~ 600 bp. In some cases, we observed a more intensive
band, indicative of HDR insertion. However, this cannot
be interpreted as a greater proportion of editing events
mediated by HDR because PCR preferentially amplifies
short amplicons (Fig. 2c). We attempted to quantitate the
HDR vs. NHEJ insertion by droplet digital PCR (ddPCR),
but failed because the ddPCR chemistry does not effect-
ively amplify amplicons greater than 250 bp.
We then conducted pJET cloning using the PCR prod-
ucts. Sanger sequencing showed expected junction se-
quences for HDR and NHEJ insertions (Fig. 2d and
Additional file 1: Figure S3). We noticed that the left
homology arm contains 20 bp of exon 13 (E13) and in-
tron 13 (In13) and 39 bp of exon 14 (E14). NHEJ inser-
tion of pDonor is expected to create two identical copies
of intron 13, which may lead to two possible splice iso-
forms (Additional file 1: Figure S4A). To distinguish
Fig. 1 High-level insertion editing of the liver at Alb by a double-cut donor after hydrodynamic injection. a Schematic of hydrodynamic injection.
Plasmids encoding Cas9 and a sgRNA targeting the Alb stop codon (sgAlb), together with an HDR template (pDonor), were delivered to the liver
by hydrodynamic tail vein injection. b Schematic of genome editing at the Alb stop codon. Knock-in of promoterless BDDF8 expression cassette
at Alb was achieved by Cas9-sgAlb-mediated simultaneous cleavage of the genome and the double-cut donor pD-tdTomato-BDDF8-sg. The pD-
sg template carries 600-bp homology arms, flanked by Cas9-sgAlb recognition sequences. Successful integration and transcription will produce
three proteins (Alb, tdTomato, and BDDF8) as the result of E2A-mediated ribosomal skipping. c Knock-in efficiencies were determined by FACS
analysis of tdTomato+ cells. Representative FACS diagrams are shown. d The double-cut donor considerably increases insertion efficiency in
mouse liver cells after CRISPR-mediated dsDNA breakage. e Editing with the double-cut donor increases coagulant activity of F8. n = 12 mice for
both conventional pD-tdTomato-BDDF8 and double-cut pD-tdTomato-BDDF8-sg donors. Omitting one or two editing components (n = 4 for
each) served as negative controls. An unpaired t test with Welch’s correction was used for statistical analysis; ***P < 0.001. f A confocal liver
section from edited mice shows expression of tdTomato in cells with hepatocyte morphology (representative of n = 5 mice). Scale bars
are 100 μm
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these possibilities, we designed primers to amplify the
Alb-BDDF8 fusion transcript and observed only one
band in the liver gDNA samples from five independent
mice (Fig. 2e). Sequencing of the RT-PCR product
showed correct splicing of Alb E13 and E14, and precise
linkage of E14 coding sequence and E2A-BDDF8 (Fig. 2f
and Additional file 1: Figure S4B-D). We speculate that
the aberrant E14-E13 in-frame fusion exon was skipped
for unknown reasons, likely because it is flanked by two
identical introns. Together, these data demonstrate that
both NHEJ and HDR insertions of the donor plasmid
lead to the correct fusion transcript.
Presence of various NHEJ insertion patterns at Alb
After cutting the double-cut BDDF8 donor in the cells,
two fragments are released: BDDF8 and the plasmid
backbone. Each of these fragments can insert at the
dsDNA break via NHEJ in forward or reverse orientation
(Fig. 3a). We designed eight pairs of primers (F8a-F,
F8a-R; F8b-F, F8b-R; F8c-F, F8c-R; F8d-F, F8d-R; BB1-F,
BB1-R; BB2-F, BB2-R; BB3-F, BB3-R; BB4-F, BB4-R) to
amplify the eight possible NHEJ junctions. After validat-
ing the specificity of the primers (Fig. 3b), we conducted
ddPCR to measure the precise copies of each NHEJ pat-
tern (Fig. 3c). Copies of the Actb gene served as a load-
ing control in each reaction (Additional file 1: Figure
S5). Summary of ddPCR data of five mice sacrificed
3 weeks after injection showed 0.002–0.02 copies per
haploid genome for each type of insertion (Fig. 3d).
Of interest, we observed similar insertion events of the
BDDF8 cassette (~ 5.5 kb) and the plasmid backbone (~
2.2 kb), suggesting that large fragments can also effectively
insert into the genome via NHEJ. If the fragment is
inserted at the Cas9-sgAlb cleavage site without significant
modification, we would expect identical copies of the left
and right junctions. However, we observed significantly
Fig. 2 NHEJ and HDR mediated BDDF8 knock-in at Alb stop codon. a Schematic of genome editing at the Alb stop codon. Knock-in of
promoterless BDDF8 expression cassette at Alb through NHEJ or HDR was achieved by Cas9-sgAlb mediated simultaneous cleavage of the
genome and the double-cut donor pD-BDDF8-sg. The pD-sg template carries 600-bp homology arms. Knock-in by NHEJ or HDR mechanism can
be differentiated by the size of the PCR products. HDR = 800 bp and NHEJ = 1400 bp. The left homology arm spans from the middle of exon 13
to the sgAlb target site. The right homology arm spans intronic sequence 3′ of the sgAlb target site. After integration and transcription by the
endogenous Alb promoter/enhancer, two proteins (Alb and BDDF8) are produced as the result of E2A-mediated ribosomal skipping. polyA,
polyadenylation site; WPRE, Woodchuck hepatitis virus (WHP) posttranscriptional regulatory element. b Editing with the double-cut BDDF8 donor
restores F8 activity in hemophilia A (n = 5). Treatments without one or two editing component (n = 4 for each) serve as negative controls. An
unpaired t test with Welch’s correction was used for statistical analysis; ***P < 0.001. c PCR analysis showing gene targeting mediated by both
HDR and NHEJ. Liver samples were harvested 1 week after hydrodynamic injection of Cas9-sgAlb and the donor. We analyzed both the left and
the right junctions by PCR. The locations of primers are indicated in a. PCR products were resolved by 2% agarose gel. gDNA from untreated
mice (WT) serves as a negative control. d The identity of the NHEJ and HDR PCR products was confirmed by sequencing. Shown is the Sanger
sequencing data of the left junction. e PCR analysis showing a successful fusion of Alb and BDDF8 1 week after hydrodynamic injection of Cas9-
sgAlb and donor vectors. f DNA sequencing data confirm the correct splicing of exon 13 and exon 14, and the fusion of the E2A-BDDF8 cassette
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higher copy numbers of the left vs. right junctions for the
F8 fragment, and the reverse was true for the backbone
fragment (Fig. 3d). We reasoned that this could attribute
to the creation of a Cas9-sgAlb target site in 50% of the
junctions after precise NHEJ. The secondary cut of these
junctions might lead to relatively large deletions [23],
which would evade detection by ddPCR. To investigate
these possibilities, we sequenced the PCR products using
the Illumina platform. In support of this argument, we ob-
served 50–90% precise NHEJ whenever there was no pos-
sible secondary cut. In contrast, only 10–20% junctions
were precise NHEJ whenever precise insertion of a
template fragment created a Cas9-sgAlb target site
(Additional file 1: Figure S6).
Decreasing the length of homology arms does not affect
therapeutic effects
In the above studies, the HDR donor carries a 600-bp
homology arm at both ends (600-600). Since NHEJ in-
stead of HDR accounted for large quantities of insertion
events, we next attempted to examine the effects of
homology arm length. To this end, we designed five add-
itional pD-BDDF8-sg vectors with different lengths of
homology arms (HA600-600, HA190-130, HA190-0,
HA85-130, HA85-0) flanked by Cas9-sgDocut recogni-
tion sequences. (Fig. 4a). One week after hydrodynamic
injection of Cas9-sgAlb, which targets the Alb stop
codon on exon 14, together with one of the five pD-
BDDF8-sg plasmids, we observed 100–200% F8 activity
in all groups (Fig. 4b). No significant differences in the
plasma coagulation activity were observed, suggesting
that homology-directed repair may only play a minor
role in BDDF8 knock-in.
To investigate the knock-in patterns, we used primers
to amplify the left junction (Fig. 4a). In all representative
samples, we observed 2 bands with sizes identical to the
predicted NHEJ (higher band) and HDR (lower band)
(Fig. 4c). Sanger sequencing confirmed the identity of
these bands (Additional file 1: Figure S7). We cloned the
PCR product into a pJET vector and sequenced over 20
Fig. 3 Characterization of NHEJ-mediated donor knock-in at Alb stop codon. a Schematic of forward and reverse integrations of the BDDF8
donor or plasmid backbone. Eight pairs of primers were designed to amplify the junctions (F8a, F8b, F8c, F8d, BB1, BB2, BB3, and BB4). The red
arrow indicates the sgAlb target site. b Successful amplification of the eight junctions using designed primers. Shown is a representative result
using live gDNA from one edited mouse. The identity of these PCR products was confirmed by Illumina sequencing (Additional file 1: Fig. S6). c A
representative diagram of ddPCR analysis of the copy number of NHEJ-mediated knock-in. One hundred nanograms of gDNA was used in each
reaction. To count the total number of haploid genomes interrogated, we used a probe that targets the Actb gene. d Quantitation of copy
numbers for the eight junctions are shown. F8fwd, insertion of BDDF8 in the forward orientation; F8rev, insertion of BDDF8 in the reverse
orientation; BBfwd, insertion of plasmid backbone in the forward orientation; BBrev, insertion of plasmid backbone in the reverse orientation
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clones. We found that NHEJ accounted for over 40~70%
of all knock-in events (data not shown). It is worth
pointing out that this approach might have underesti-
mated NHEJ events due to the preferential amplification
and insertion of short PCR products.
We then conducted RT-PCR to amplify the junction
of the Alb-BDDF8 fusion transcript. We observed a sin-
gle band, indicative of precise splicing of Alb E13 and
E14, and E2A-BDDF8 in five representative samples
(Fig. 4d). Sanger sequencing of the RT-PCR products
verified these results (Fig. 4e and Additional file 1:
Figure S8). These data demonstrate that both HDR and
NHEJ knock-in lead to correct fusion transcripts.
Together, these data demonstrate that HDR editing in
hepatocytes is unnecessary for successful knock-in of a
therapeutic gene. Instead, NHEJ integration in the liver
is more efficient, even in the presence of homology
arms. As such, we decided to focus on investigating the
NHEJ-mediated integration of BDFF8 using donors
without homology.
NHEJ-mediated integration of BDDF8 at Alb intron 11 or
13 cures hemophilia A
The insertion of BDDF8 by NHEJ instead of HDR makes
it unnecessary to target the Alb stop codon. We de-
signed three sgIn13 to target intron 13 and used pD-
BDDF8-sgDocut (SA85-0) as a donor template. We
renamed HA85, which consists of 46 bp and 39 bp of the
intron 13-exon 14 junction sequence, to SA85, indicat-
ing its function as a splice acceptor. To increase the
Fig. 4 BDDF8 insertion at the Alb stop codon is predominantly through NHEJ. a Schematic of genome editing at the Alb stop codon using
double-cut BDDF8 donors with different lengths of homology arms. The pD-sg templates carry the different length of homology arms (HA600-
600, HA190-130, HA190-0, HA85-130, HA85-0), flanked by Cas9-sgDocut recognition sequences. NHEJ- or HDR-mediated knock-in can be
differentiated by the size of the PCR product using primers F1 and R1. Successful integration leads to the transcription of an Alb-BDDF8 fusion
gene, which translates to two proteins: Alb and BDDF8. b High-level F8 activity 1 week after injection of Cas9-sgAlb and double-cut pD-BDDF8-sg
donors with different length of homology arms (n = 2–5 for each group). Mice treated without donor only (n = 2) serves as a negative control. An
unpaired t test with Welch’s correction was used for statistical analysis; ***P < 0.001. c PCR analysis showing successful gene targeting by both
HDR and NHEJ. PCR analysis of the left junction in edited mice. The locations of F1 and R1 primers are shown in a. PCR products were resolved
on a 2% agarose gel. Untreated mice (WT) showed no evidence of targeting. d Quantification of NHEJ and HDR editing at the left junction using
ddPCR. Liver gDNA was extracted 1 week after editing using donor pD-BDDF8(HA85-130). We used probes targeting both the junction (NHEJ)
and HA85 (NHEJ+HDR) in ddPCR. e Amplification of the fusion transcript of Alb and BDDF8 by RT-PCR. f Sanger sequencing data show correct
splicing of exon 13 and exon 14 and the exon 14-E2A junction
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flexibility of vector combination, we flanked the BDDF8
donor with sgDocut recognition sequences so that a sin-
gle donor could be used in all cases (Fig. 5a). In this
study, we included three sets of controls: (1) two sgIn12
targeting intron 12 to form an out-of-frame fusion tran-
script, leading to no F8 expression; (2) two sgIn11 tar-
geting intron 11, which will result in a truncated Alb
and functional BDDF8; and (3) an sgRNA targeting the
stop codon on exon 14 (Fig. 5a).
We first examined the cleavage efficiency of these
sgRNAs 1 week after hydrodynamic tail-vein injection of
Cas9-sgRNA plasmids. PCR amplification of the target
regions followed by high-throughput sequencing analysis
showed that seven out of eight sgRNAs could effectively
cut its target sequence, with indel efficiencies of 2–6%
(Fig. 5b and Additional file 1: Figure S9). SgIn11-17
showed lower indel efficiencies of ~ 1%. We then hydro-
dynamically injected HA mice with pDonor, Cas9
plasmid, and two sgRNA plasmids, one cutting Alb in-
tron and another linearizing the double-cut donor plas-
mid. One week later, we examined the F8 activity in the
plasma.
Of interest, targeting intron 12 led to low levels of F8
at 10–20%. We interpreted this result as a large deletion
including exon 12 in a small portion of cells, leading to
the inframe splicing of exon 11 to exon 14 and E2A-
BDDF8 (Fig. 5c). The use of four out of five sgRNAs tar-
geting intron 11 or 13 showed high levels of F8 activity
(Fig. 5c). SgIn11-17 led to low F8 activity, which is asso-
ciated with its low cleavage efficiency (Fig. 5b). Together,
NHEJ-mediated insertion of BDDF8 at introns is a viable
therapeutic strategy.
We further characterized BDDF8 integration at the
RNA level. We designed primers to amplify the junction
between Alb exon 10 and BDDF8. Targeting intron 11
and intron 13 led to expected fusion transcripts. Of
Fig. 5 NHEJ-mediated knock-in of BDDF8 at Alb introns 11 or 13 cures hemophilia A. a Schematic of the intron targeting of BDDF8 at the mouse
Alb locus. We used ten sgRNAs in this study. The yellow box indicates the Alb sequence on the donor: 3′ end of intron 13 (46 bp) and 5′ end of
exon 14 before the stop codon (39 bp), which serves as a splice acceptor. After cut at an Alb intron, the linearized donor will integrate via the
NHEJ repair pathway. Right panels show the predicted fusion mRNA and protein products. b Assessment of sgRNA cleavage efficiency by
Illumina sequencing 1 week after injection of Cas9-sgRNA. An unpaired t test with Welch’s correction was used for statistical analysis; ***P < 0.001.
c Differential F8 activity after knock-in of BDDF8 donor at different loci of the Alb gene. sgRNAs targeting intron 1 and intron 12 serve as negative
controls. d Analysis of Alb-BDDF8 fusion transcripts by RT-PCR. e DNA sequencing data confirmed the correct splicing of different Alb exons or
skipping an Alb exon or inclusion of an exon from the plasmid backbone
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interest, in some samples, we also observed a lower
band, indicative of exon 11 or exon 13 deletion
(Additional file 1: Figure S10). We interpreted the data
as large deletions in a small portion of cells.
Surprisingly, RT-PCR analysis detected two bands in all
intron 12-targeting samples. Sanger sequencing revealed
that the lower band was the predicted fusion transcript
that lacks exon 13. However, the higher band had an extra
206 bp that matched the plasmid backbone, inserted be-
tween exon 12 and exon 14. We used the Human Splice
Finder tool [24] to analyze the backbone sequence and
identified an exon of 206 bp with an identical sequence to
the insert (Additional file 1: Figure S11). As such, we
speculate that the insertion of the plasmid backbone to-
gether with the BDDF8 donor led to this incident.
Collectively, our data demonstrate that targeting in-
trons is a feasible strategy for in vivo gene therapy.
There may be, however, unexpected fusion transcripts
due to the occasional large deletions or insertion of vec-
tor backbone.
AAV-CRISPR therapy cures hemophilia A mice
We have conducted a series of experiments to optimize
the conditions for knock-in of BDDF8 at Alb. In the
above studies, we used hydrodynamic injection for the
delivery of editing plasmids to mouse liver. We then
attempted to use adeno-associated vector (AAV) to de-
liver BDDF8 donor and CRISPR components for clinic
translation. We chose AAV8 because serotype eight
adeno-associated vector can effectively transduce mouse
hepatocytes [25]. After deletion of the homology se-
quence, the AAV-BDDF8 donor flanked by splice ac-
ceptor and a rabbit beta-globin polyadenylation signal
(126 bp) has a genome size of 5009 bp, which is within
the upper limit for effective AAV packaging. For the
Cas9 vector, we replaced the human EF1 promoter (1.2
kb) with the mouse U1a promoter (251 bp), resulting in
an AAV with a genome size of 4898 bp [26]. In the
sgAlb vector, we added a stuffer of 2.5 kb in length (Fig.
6a). Droplet digital PCR analysis of AAV titers showed
that all the vectors could be adequately packaged.
In the preliminary AAV-CRISPR-BDDF8 study, we se-
lected three sgAlb-Ins that showed effective NHEJ inser-
tion of BDDF8 after hydrodynamic injection of plasmids.
We injected adult HA mice intravenously with 1 × 1011
genome copies (GC) of AAV-Cas9, 1 × 1011 GC of AAV-
sgAlb, and 5 × 1011 GC of AAV-BDDF8. Follow-up on
the mice at 1, 2, and 4 weeks after injection showed a
stable F8 activity of 100–200% (Fig. 6b). As expected,
the injection of the promoterless AAV-BDDF8 alone
showed no therapeutic effect (Fig. 6b). These preliminary
results demonstrate the feasibility of AAV-CRISPR ther-
apy in treating hemophilia A.
Recent reports showed high-level AAV integration in
Cas9-induced double-strand breaks (DSBs) [27, 28]. We
thus designed primers to amplify the junction sequences
after insertion of AAV-BDDF8 or AAV-Cas9 at Alb in-
tron 13–371 or 527 (Additional file 1: Figure S12A).
Fig. 6 AAV-CRISPR therapy cures hemophilia A mice. a Schematic of the AAV vectors used in the study and experimental overview for in vivo
studies. SA85 on the donor functions as a splice acceptor. b Stable F8 activity after injection of AAV-Cas9, three different AAV-sgRNAs targeting
Alb introns 11 or 13, and AAV-BDDF8 donor. (n = 3 for each group). A group of mice treated with AAV-BDDF8 donor only (n = 3) serves as a
negative control
Zhang et al. Genome Biology          (2019) 20:276 Page 8 of 17
PCR analysis identified the junction sequences of all pos-
sible AAV insertion patterns, demonstrating the inser-
tion of both AAV-F8 and AAV-Cas9 sequences in
double-strand break sites (Additional file 1: Figure S12
BC). We conducted pJET cloning and picked over 100
colonies for Sanger sequencing and found that NHEJ-
mediated insertion led to an average of ~ 15 bp deletions
in the genome cleavage site and ~ 80 bp deletion of AAV
ITR (Additional file 1: Figure S13).
Long-term, persistent BDDF8 expression after transient
immunosuppression
We observed 50–200% F8 bioactivity 1 week after the ad-
ministration of Cas9-sgAlb and pD-BDDF8-sg donor plas-
mids, but F8 levels decreased considerably to ~ 14% in 6
out of 13 mice 3 weeks later (Additional file 1: Figure S14).
The immune response to exogenously infused F8 is a major
complication in the treatment of hemophilia A patients
[29]. Thus, we assessed F8 inhibitor titers with the
Nijmegen-Bethesda assay (Additional file 1: Figure S14).
Compared to the untreated HA mice, there were no detect-
able inhibitors in F8-stable mice, but a significant increase
in F8-decline mice, indicating that the humoral response to
F8 contributed to decreased F8 activity. As a positive con-
trol for the reaction against F8, we injected the mice with a
plasmid in which the EF1 promotor drives BDDF8
expression, and high-titer F8 inhibitors were detected
(Additional file 1: Figure S15).
We decided to use immunosuppressants to control the
immune reaction. We tracked the F8 coagulant activity
after hydrodynamic injection of Cas9-sgAlb and the donor
pD-tdTomato-BDDF8-sg for 12 weeks after transient im-
munosuppression. We chose the combination of methyl-
prednisolone (MPS) and cyclophosphamide (CTX), which
have been used in HA gene therapy previously [6, 30]. In-
traperitoneal injection of MPS (50mg/kg) and CTX (50
mg/kg) seven times in 3 weeks increased the 3-month F8
stability to > 80% (Additional file 1: Figure S16). We then
investigated how the immunosuppression maintained F8
stability. We observed an increase of edited liver cells
(tdTomato+) from 1.0 to 2.2% after immunosuppression at
3 weeks, suggesting inhibition of the cellular immune re-
sponse (Additional file 1: Figure S16). We also observed a
significantly decreased humoral response against F8
(Additional file 1: Figure S16). These data demonstrate
that transient immunosuppression can effectively control
both cellular and humoral immune reactions to F8, lead-
ing to a sustained therapeutic efficacy.
Life-long efficacy and safety of genome editing therapy
for hemophilia A
In the above studies, we tracked the F8 activity after
hydrodynamic injection of plasmids for up to 3months.
We have now followed up on ~ 100 treated mice for more
than 1 year (Fig. 7a and Additional file 1: Figure S17) with
or without transient immunosuppression. Fifteen animals
have been followed up for 2 years (the maximum lifespan
of HA mice in our experience). We observed occasional
fluctuations in F8 activity in individual mice, likely due to
technical reasons. In all mice, however, we found overall
sustained F8 activity, ~ 100% of normal levels, ranging from
20 to 400% (Fig. 7a and Additional file 1: Figure S17). To
assess the coagulation activity of treated HA mice, we con-
ducted the tail-clip challenge assay. As expected, 0% (zero
out of seven) of untreated HA, 100% (six out of six) of
treated HA, and 100% (five out of five) of wild-type C57BL/
6 mice survived the traumatic hemorrhage (Fig. 7b).
We sacrificed multiple, randomly chosen mice 1 year
after treatment for detailed analysis. Hematoxylin and
eosin (H&E) staining and gross analysis of the liver
showed no anatomical differences between treated and
untreated mice (Fig. 7c). Serum markers of liver damage
such as aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), total bilirubin (TBIL), and total al-
bumin (ALB) were indistinguishable between treated
and untreated mice (Fig. 7d). These data suggest that
hydrodynamic injection of CRISPR components in the
liver is well-tolerated in mice.
We also observed no indels in the organs other than
in the liver (Additional file 1: Figure S18), consistent
with the reports that hydrodynamic injection predomin-
antly delivers nucleic cargos to hepatocytes [16]. We
thus focused the further analysis on our target organ,
the liver. Of note, the pattern of indels at the Alb locus
of liver cells was indistinguishable when analyzed 3 weeks
vs. 1 year after treatment (compare Additional file 1:
Figure S1B to Additional file 1: Figure S18 (treated
liver)), suggesting that indels at Alb have no deleterious
effects on hepatocytes. Mixed results on CRISPR-Cas9-
mediated off-target editing have been reported [31, 32].
We analyzed the livers from 5 untreated and treated
mice by PCR amplification of putative off-targets
followed by deep sequencing. We found no evidence of
indels at 20 different genomic targets that were the most
likely sites for off-target cleavage (Additional file 1:
Figure S19). In addition, immune responses to F8 were
undetectable (Fig. 7e).
We also did not observe any changes in the growth or
weight over 18months of observation. In some mice, both
BDDF8 and tdTomato were inserted at Alb, which allows
for imaging analysis of edited cells. Two-photon imaging
and 3D reconstruction of the liver sections from HA mice
1 year after hydrodynamic injection showed an even distri-
bution of tdTomato+ cells in the liver (Fig. 7f and
Additional file 3: Video S2). Of note, we observed clusters
of tdTomato+ liver cells, suggesting that the edited hepa-
tocytes have divided one to two times in 1year. However,
we did not see any large clumps of edited cells, indicative
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of non-clonal expansion and thereby demonstrating the
long-term safety of this approach. To further track the
clonal evolution of edited cells, we used ddPCR to detect
the copy numbers of NHEJ-mediated knock-in 1 year after
treatment (Fig. 7g). Similar to the results obtained at
1 week after treatment, we observed the presence of all
types of NHEJ insertions and at similar ratios. These data
demonstrate that the insertion of the plasmid backbone or
donor sequence in any orientation has no deleterious ef-
fects on edited hepatocytes.
Discussion
In this study, we applied a CRISPR-Cas9 genome editing
approach to knock in BDDF8 at the Alb locus and
achieved high-level, long-term stable F8 expression. We
used hydrodynamic tail-vein injection to prove the
principle and also succeeded in delivering editing com-
ponents using AAV. We found that NHEJ is a more effi-
cient DNA damage repair pathway than HDR in the
liver. NHEJ-mediated knock-in at introns makes it pos-
sible to identify the best target with a high cleavage
efficiency and low off-target effects. As such, NHEJ
knock-in at introns may be a favorable editing approach
for in vivo gene editing. These studies lay the foundation
for further development of the AAV-CRISPR-F8 strategy
into clinical therapy.
Several groups have used ZFN or CRISPR-mediated
gene targeting at different loci to achieve therapeutic
levels of gene expression in hemophilia B mouse models
[7–13, 19]. Some studies used ZFN to target intron 1 of
the Alb gene [7–9], while others targeted right before its
stop codon without using a nuclease [19]. Targeting in-
tron 1 or intron 2 of the F9 gene has also been
attempted [12, 13]. Only one earlier study targeted BDDF8
at intron 1 of the Alb gene using ZFN [9], but they ob-
served merely 20–30% F8 activity for a short period. Here,
we cured hemophilia A mice by using CRISPR-Cas9-
mediated BDDF8 gene knock-in and achieved life-long
stable therapeutic F8 levels of ~ 100%. To our knowledge,
this is the first report of successful CRISPR-mediated F8
targeting in hemophilia A mice. CRISPR-Cas9 has several
advantages compared with ZFN or transcription activator-
Fig. 7 Long-term efficacy and safety in BDDF8-edited hemophilia A mice. a Long-term follow-up on the F8 activity of hemophilia A mice. The
animals were hydrodynamically injected with Cas9-sgAlb and the double-cut donor pD-BDDF8-sg (n = 15). The exact P value is shown by a one-
way ANOVA analysis. b Treated mice survive a tail-clip challenge. Wild-type C57BL/6 (WT) mice (n = 5) served as a positive control. c Hematoxylin
and eosin (H&E) staining of the liver sections of untreated and treated HA mice 1 year after injection. Shown are representative images from five
mice. d Liver toxicity markers 1 year after treatment. AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; Alb, total
albumin (n = 10). No significant differences were observed between untreated HA mice (n = 10) and treated HA mice (n = 10) by unpaired t test
with Welch’s correction. e Levels of F8 inhibitors in mouse plasma measured by Bethesda assay. Untreated 1 year (n = 8); treated (n = 8). An
unpaired t test with Welch’s correction was used for statistical analysis. ns, not significant. f Two-photon imaging of liver tissues indicates a stable
expression of tdTomato. CD144 (VE-cadherin) stains the liver vasculature structure; edited cells (tdTomato-BDDF8) were pseudo-colored as green.
Shown is a representative image of n = 4 mice. g ddPCR analysis indicates the long-term presence of junctions of NHEJ mediated knock-in 1 year
after treatment. Schematic and detailed information was presented in Fig. 3
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like endonuclease (TALEN) in genetic diseases. First, the
straightforward design of sgRNA allows for a rapid screen-
ing of large quantities of potential targets. Second, ZFN
and TALEN often leave staggered DNA ends, whereas
CRISPR-Cas9 leaves clear-cut ends, which favor NHEJ in-
sertion of donor template.
We initially aimed for the precise insertion of the BDDF8
donor at Alb. However, molecular characterization showed
that NHEJ played a predominant role in donor integration.
This result is in sharp contrast to the almost exclusive edit-
ing by HDR in human pluripotent stem cells and other cell
lines in culture [14]. The discrepancy could be attributed to
different proportions of cells in the active cell cycle. NHEJ
is the primary mechanism used to repair DSBs [33], and
HDR rarely occurs in post-mitotic adult tissues, such as the
skeletal muscle and liver [34]. As such, in order to treat
genomic diseases by postnatal genome editing in vivo, we
should exploit the NHEJ repair mechanisms after CRISPR-
Cas9-mediated dsDNA breaks. To promote unidirectional
insertion by NHEJ, Belmonte’s lab proposed a homology-
independent targeted integration (HITI) strategy [22]. In
this study, we wished to guide HDR insertion using a
double-cut donor instead of NHEJ. NHEJ-mediated inser-
tion in the liver is a serendipitous finding. As such, the
sgRNA-PAM orientations in the double-cut donor were
different from the HITI design. Would we have used the
HITI design, we might expect more significant therapeutic
effects due to the predominant forward insertion of the
donor.
The double-cut donor-mediated HDR editing [14] is
also termed homology-mediated end joining (HMEJ)
[35]. Both use knock-in templates flanked by sgRNA-
PAM sequences with different lengths of homology arms
that are released after Cas9-sgRNA cleavage. In our de-
sign, we used homology arms of 300–600 bp, whereas
the HMEJ approach uses longer homology arms of up to
800 bp. In comparison, microhomology-mediated end
joining (MMEJ) uses short homology arms of 5–20 bp.
In our experience, MMEJ is much less efficient than
HMEJ in guiding HDR editing in mammalian cells.
Many gene therapists have chosen the Alb locus for tar-
geted gene insertion to achieve high-level gene expression
[9, 19, 36]. One concern is that the insertion of a thera-
peutic gene may decrease Alb expression. Indeed, we ob-
served an ~ 5% decrease in total albumin protein levels in
treated mice relative to untreated mice in circulation after
1-year treatment, albeit the difference was not statistically
significant (Fig. 7d). Furthermore, reverse insertion of a
transgene construct, Cas9-sgRNA, or plasmid backbone
may lead to aberrant albumin protein, raising a safety con-
cern. However, the long-term presence of all types of
NHEJ insertions in edited liver cells argues against the po-
tential risk of aberrant albumin. In further support of
targeting the Alb locus in gene therapy, a 2-year follow-up
on treated mice found no adverse effects.
Off-target cleavage is a significant safety concern for
genome editing. A recent study showed that appropri-
ately designed guide RNAs could direct efficient in vivo
editing in mouse livers with no detectable off-target mu-
tations [37]. We evaluated the specificity of sgAlb-E14
using next-generation sequencing validation on the top
20 potential off-target sites identified by a computer al-
gorithm in liver DNA from treated animals. Despite effi-
cient on-target editing, we did not detect any off-target
activity, indicating a high specificity of sgAlb-E14 (Add-
itional file 1: Figure S19). Another safety concern is the
large deletions [23]. We provided RT-PCR evidence
showing that a large deletion is present in a small por-
tion of cells, which leads to the deletion of one extra
exon in transcripts. However, we did not observe any
deleterious consequences due to the deletion of a large
piece surrounding the Cas9-sgRNA cut sites. Since we
did not detect off-target cleavage of Cas9-sgAlb, we do
not expect appreciable deletions at other sites of the
genome.
After dsDNA breaks, AAV preferentially integrates at
the break site. However, a few AAV vectors may still be
able to randomly integrate into the host genome, albeit at
a low frequency [38]. One study showed that genes known
to have higher expression in the liver, such as albumin,
are hotspots for AAV integration [39]. More recently, high
levels of AAV integration into Cas9-induced double-
strand breaks were observed in cultured mouse tissues
[27]. Moreover, using the Nextera-transposon-based li-
brary preparation method for unbiased sequencing, AAV
integrations were observed in all treated mice [28]. In our
study, we also identified insertions of the AAV-F8 and
AAV-Cas9 sequence at CRISPR cleavage sites. Although
AAV-mediated expression of Cas9 or integration of Cas9
did not lead to significant genome-wide genotoxicity, per-
sistent expression due to AAV-Cas9 integration may trig-
ger immune depletion of edited cells [40, 41]. Developing
strategies to minimize AAV-Cas9 integration is imperative
before initiating clinical trials of AAV-CRISPR therapies.
Toward that goal, the use of a self-deleting AAV-CRISPR
system may be able to effectively remove Cas9 protein in
mouse liver while retaining efficient in vivo editing of en-
dogenous targets [42].
Several types of AAV vectors are currently being
used in ~ 200 clinical trials, and there has not been
any reported increase in the incidence of cancer [43].
These data suggest the safety of AAV vectors in clin-
ical practice. However, further studies are required to
examine the safety of AAV-CRISPR therapy for
hemophilia A.
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Conclusions
In summary, we have successfully cured hemophilic
mice by delivering CRISPR-Cas9 genome-editing tools,
using a high-speed injection of plasmids or transfusion
of AAV vector in vivo. The life-long stable therapeutic
effect is a significant advantage of using AAV-CRISPR-
Cas9 over the conventional AAV vector treatment.
Long-term follow-up on the AAV-CRISPR-treated HA
mice and comprehensive investigation into the safety
profiles will be necessary before the application of this
technology in treating hemophilia patients.
Methods
Cas9-sgRNA plasmid construction
We used the CHOPCHOP website (https://chopchop.rc.
fas.harvard.edu/) to design sgRNA targeting the Alb stop
codon in exon 14 and introns 1, 11, 12, and 13. In most
experiments of this work, we used either sgAlb-E14
(GTTGTGATGTGTTTAGGCTA) or sgAlb for simpli-
city. We cloned the pU6-sgRNA vector using the NEB-
uilder HiFi DNA Assembly Kit (New England Biolabs).
Sequences of all the sgRNAs used in this work are listed
in Additional file 1: Table S1. We used humanized Cas9
from Streptococcus pyogenes (SpCas9) flanked by nuclear
localization sequence (NLS) or Cas9 for simplicity. The
pEF1-Cas9-Wpre-PolyA vector has been previously pub-
lished [44]. AAV-U1a-Cas9 has been used in an earlier
study [26]. AAV-BDDF8 was cloned by inserting SA85-
E2A-BDDF8-PolyA between inverted terminal repeats of
the pAAV2 plasmid. We constructed AAV-sgRNA vec-
tors by PCR amplification of U6-sgRNA and insertion of
a 2.5-kb stuffer from the Alb enhancer. All the vectors
were verified by endonuclease digestion and Sanger se-
quencing (MCLAB).
Donor plasmid construction
To construct pDonor plasmids targeting the Alb stop
codon, the left and right homology arms of 600 bp
(HA600-600) were amplified from mouse genomic
DNA, with the stop codon removed and in-frame linked
with the E2A sequence; the inserted Tomato, BDDF8,
F8, or mNeonGreen were amplified from other vectors
in the lab by PCR. The sgAlb target sequence, together
with the PAM sequence (GTTGTGATGTGTTTAGGC
TAAGG), was tagged upstream of the left homology
arm and downstream of the right homology arm. In
some double-cut donor vectors, we used the sgDocut se-
quence (GGTGGTGCAGATGAACTCCATGG). Mul-
tiple inserts and plasmid backbone were linked together
using the NEBuilder HiFi DNA Assembly Kit. pD-
mNeonGreen, pD-mNeonGreen-sg (where sg indicated
the double-cut design), and pD-BDDF8-sg (HA190-130,
HA190-0, HA85-130, HA85-0) were constructed using
the same method. Correct clones were identified by
endonuclease digestion and Sanger sequencing.
Hemophilia A mice and hydrodynamic injection
We purchased the hemophilia A (HA) mice bearing an F8
exon 16 knockout on a 129 × B6 background from the Jack-
son Laboratory (Bar Harbor, ME), which was initially ob-
tained from Dr. H. Kazazian (University of Pennsylvania)
[20]. The mice were housed and maintained at the State
Key Laboratory of Experimental Hematology (SKLEH,
Tianjin, China). Animal experiments were conducted ac-
cording to the protocols approved by the Institutional Ani-
mal Care and Use Committee of SKLEH and the Institute
of Hematology. Vectors for hydrodynamic tail vein injec-
tion were prepared using the EndoFree MaxiPrep Kits (Qia-
gen) or ZymoPURE II Plasmid Maxiprep Kit (Zymo
Research). We screened endotoxin using Lyophilized ame-
bocyte lysate LAL/TAL reagent (Xiamen Bioendo Technol-
ogy) and abandoned endotoxin-contaminated plasmids.
Before in vivo injections, we diluted plasmid DNA using so-
dium lactate Ringer’s solution (China Otsuka Pharmaceu-
tica). For hydrodynamic injection, a volume equivalent to
10% of mouse body weight was administered via the tail
vein in 5–6 s into 5–8-week-old HA mice. The amount of
plasmid DNA was 10 μg each for Cas9, sgRNA, and pDo-
nor. To prevent bleeding, we injected 0.5 IU F8 protein
(Xyntha; Wyeth Pharmaceuticals) in each mouse, together
with the editing plasmids.
Determination of tdTomato+ or mNeonGreen+ liver cells
by flow cytometry
To determine the percentage of liver cells that were
tdTomato+ or mNeonGreen+, small portions of livers
were cut off and fixed in a 10% formalin solution for 3–
4 h. Fixed livers were ground in PBS and filtered through
70-μm cell strainers. We added DAPI before analyzing
the cells on a BD FACS Aria III flow cytometer. At least
1 × 105 events were analyzed to detect the percentage of
tdTomato+ or mNeonGreen+ cells. Liver cells from un-
treated mice served as a control. To analyze the tdTo-
mato+ or mNeonGreen+ cells, we first gated the DAPI+
cells and then tdTomato+ or mNeonGreen+ cells using
the untreated mouse liver cells as negative controls.
Blood collection and plasma isolation
For plasma isolation, blood samples were collected by
tail vein clipping and bled into a microtube containing
3.2% sodium citrate, which was adjusted to 10% of the
blood volume obtained. When 100 μl of blood was col-
lected, styptic powder (Miracle Corp) was used to stop
the bleeding. Samples were centrifuged at 2000×g for 15
min at 25 °C. The plasma fraction was removed, trans-
ferred to a new tube, immediately frozen on dry ice, and
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stored at − 80 °C. Plasma samples were thawed quickly
at 37 °C immediately before measuring F8 bioactivity.
F8 coagulation assay
We used a one-stage aPTT-based clotting assay to meas-
ure the F8 coagulation activity with a Sysmex CA1500
system (Sysmex, Kobe, Japan). Siemens reagents (Sie-
mens; Marburg, Germany) including Dade Actin acti-
vated cephaloplast in reagent (Siemens; B4218-1) and
coagulation F8-deficient plasma (Siemens; OTXW17)
were used. The mouse plasma samples were diluted with
Dade Owren’s Veronal Buffer (Siemens; B4234-25) by a
factor of 4. The F8 activity was performed by mixing 5 μl
of diluted mouse sample plasma with 45 μl of Dade
Owren’s Veronal Buffer and 50 μl of F8-deficient plasma
and 50 μl of aPTT reagent (Dade Actin activated cepha-
loplast in reagent), followed by a 120-s incubation at
37 °C. Coagulation was initiated after the addition of
50 μl of 25 mM calcium chloride. Time to clot formation
was measured by the Sysmex CA1500 system. A stand-
ard curve was prepared by diluting the human calibra-
tion plasma (Siemens), and the plasma obtained from
wild-type mice served as a positive control.
F8 inhibitor assay
We used a modified Bethesda assay to determine the
titer of F8-neutralizing inhibitors [45–47]. Normal
plasma was prepared by mixing 100 μl of F8-deficient
plasma with 0.15 IU recombinant F8 protein (Xyntha) to
make 100% F8 activity of normal plasma. Mouse plasmas
were thawed at 37 °C and incubated at 56 °C for 30 min
to inactivate F8 activity. Normal plasma (100 μl) was
mixed with an equal volume of either inactivated mouse
plasma (test mixture) or 0.1M imidazole buffer pH 7.4
(control mixture). After 2 h of incubation at 37 °C, the
relative percentage of F8 coagulation activity of the test
mixture compared to the control mixture (residual F8
coagulation activity) was determined. One Bethesda unit
(BU) was defined as the amounts of inhibitors that result
in a 50% decrease in residual F8 coagulation activity.
When residual F8 activity of the undiluted sample was
below 25%, it was retested by diluting in 0.1M imidazole
buffer pH 7.4 until a residual F8:C activity of 25 to 75%
was obtained.
Droplet digital PCR
Genomic DNA was extracted from untreated and
treated HA mice. The DNA concentration was deter-
mined by Qubit 4 Fluorometer (Thermo Fisher Scien-
tific). As recommended for ddPCR analysis, primers
were designed to amplify products of 150–250 bp. The
primer and probe sequences are listed in Additional file 1:
Table S2. The reaction mixtures contained 2× ddPCR
Supermix for Probes (no dUTP) (Bio-Rad, Cat#: 186–
3010), primers for target and reference assay (final con-
centrations of 900 nM each), FAM- or HEX-labeled
probes (IDT) for both assays (final concentrations of
250 nM each), and template (100 ng) in a final volume of
20 μl. Standard reagents and consumables supplied by
Bio-Rad were used, including cartridges, gaskets, droplet
generation oil, and droplet reader oil. After droplet gen-
eration, we carefully transferred them to a 24-well PCR
plate and sealed the plate with the PX1 PCR Plate Sealer
(Bio-Rad). The PCR conditions were 95 °C for 10 min,
followed by 40 cycles of 94 °C for 30 s, 60 °C for 1 min,
and 98 °C for 10 min, then hold at 4 °C. The ramp rate
was set at 2 °C/s. Droplets were read using the QX200
Droplet Reader (Bio-Rad). We included a no-template
control (NTC) and negative control for each reaction.
Data analysis was conducted using the QuantaSoft Soft-
ware version 1.7.4.0917. Actb was used as a loading con-
trol, having a single copy per genome. All DNA samples
were run at least twice.
Verification of NHEJ vs. HDR-mediated knock-in by PCR
and Sanger sequencing
Genomic DNA from mouse liver tissue was extracted
using DNeasy Blood & Tissue Kit (Qiagen). To distin-
guish between the HDR- and NHEJ-mediated knock-in,
we conducted PCR using one primer that anneals to the
genome sequence outside of the homology arm and an-
other targeting the donor-specific sequence. The primers
used for this experiment are listed in Additional file 1:
Tables S3 and S4. We used the KAPA HiFi HotStart
ReadyMix (KAPA Biosystems) for PCR. The cycling con-
ditions were 98 °C for 2 min, followed by 35 cycles of
98 °C for 10 s, 64 °C for 5 s, 68 °C for 5 s, and 72 °C for
15 s. After separation on 1–2% agarose gels, we purified
the selected DNA bands using QIAquick Gel Extraction
Kit (Qiagen). The purified PCR product was inserted
into a pJET1.2 vector (Thermo Fisher). We picked mul-
tiple clones for Sanger sequencing.
Detection of fusion Alb-hF8 transcript by RT-PCR
A 30-mg piece of liver tissue was snap-frozen using li-
quid nitrogen. The samples were then ground into a fine
powder in liquid nitrogen with a pre-chilled mortar and
pestle and mixed immediately with RLT (Qiagen RNeasy
Mini Kit, Valencia, CA) lysis buffer. DNA was extracted
following the manufacturer’s instructions. cDNAs were
synthesized using TransScript First-Strand cDNA Syn-
thesis SuperMix (TransGen Biotech) from 1 μg RNA.
PCR was performed using KAPA HiFi HotStart Ready
Mix (KAPA Biosystems) to detect hybrid murine Alb-
hF8 mRNA. The following pairs of primers were used:
T237-CTTGGTCAAAACCAACTGTGA, which anneals
to exon 10 of Alb, and T385-ATCGCAAAAGGCAC
AGAAAG, which anneals to human F8. The cycling
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condition was 98 °C for 2 min followed by 35 cycles of
98 °C for 10 s, 64 °C for 5 s, 68 °C for 5 s, and 72 °C for
20 s. The PCR products were sequenced.
Immunosuppression
For transient immunosuppression, cyclophosphamide
(50 mg/kg per injection) and/or methylprednisolone (50
mg/kg per injection) was intraperitoneally injected on
the day of vector injection, followed by biweekly injec-
tions for 3 weeks (seven times in 3 weeks).
AAV vector packaging, purification, and titering
All the AAV8 vectors were produced by three-plasmid
transfection at the SKLEH Vector Core. We performed
PEI-based transfections in 15-cm dishes when HEK293T
cells reached 80% confluency [48]. The three plasmids
were (1) cis plasmid pAAV-U1a-Cas9, pAAV-BDDF8
(donor), or pAAV-U6-sgRNA; (2) trans plasmids
pAAV2/8 containing the AAV2 rep gene and capsid
protein genes from AAV8; and (3) adenovirus helper
plasmid pHelper (Cell Biolabs). For each microgram of
DNA transfected, 2 μg of PEI Max (Polysciences) was
used. Plasmids at a ratio of 2:1:1 (20 μg of helper plas-
mid, 10 μg of AAV cis plasmid, 10 μg of trans plasmid
per plate) were used. Three days after transfection, 10 ml
of fresh DMEM-10% FBS was added, and incubation
continued for 2 days. We then added 25 units/ml Benzo-
nase (Santa Cruz Biotechnology) and 500 mM NaCl
(Sigma). Two hours later, the supernatant was harvested
and clarified by centrifugation at 5000×g for 10 min. The
feedstock was then concentrated by tangential flow fil-
tration (TFF), using a TFF capsule with a 300-kDa mo-
lecular weight cutoff (Pall Minimate). A 15-fold
concentration of AAV vectors was further purified by
ultracentrifugation through an iodixanol density gradi-
ent, then concentrated and dialyzed against PBS, as pre-
viously described [49].
The physical particle titers (genome copies per milli-
liter) were determined by droplet digital PCR using
primers targeting U6, F8, or Cas9 [50]. Vector aliquots
were diluted 10-fold and treated with DNase I (ABM;
400 U/ml) at 37 °C for 30 min, followed by heat inactiva-
tion at 95 °C for 5 min. Treated samples were then fur-
ther diluted 100,000-fold in dilution buffer using nano
water with added 0.05% Kolliphor P188 (Sigma; also
known as Pluronic F68). The reaction mixtures were as-
sembled with the recommended ddPCR Supermix (Bio-
Rad) and template (1 μl) in a final volume of 20 μl. The
positive or negative droplets were read from the QX200
reader.
Tail vein injection of AAV
All AAV vectors used in this study passed an endotoxin
assay using the amebocyte lysate LAL/TAL reagent
(Xiamen Bioendo Technology). We injected hemophilia
A mice with 1 × 1011 AAV8-Cas9, 1 × 1011 AAV8-
sgRNA, and 5 × 1011 AAV8-BDDF8. Injection with
AAV8-BDDF8 donor only served as a control. AAV vec-
tors were diluted to 200 μl in phosphate-buffered saline
plus 0.001% Kolliphor P188 before the tail vein injection.
Detection of AAV vector integration by PCR and Sanger
sequencing
To determine the AAV vector integration at the gene
editing site mediated by AAV-CRISPR-Cas9, we ex-
tracted genomic DNA from mouse liver using DNeasy
Blood & Tissue Kit (Qiagen). One primer was designed
to anneal to the Alb target site and the other primer to
Cas9 or BDDF8. Additional file 1: Table S5 lists the pri-
mer sequences for this study. We used the KAPA HiFi
HotStart ReadyMix (KAPA Biosystems) for PCR. To
successfully amplify AAV ITR-containing sequences, we
added 5–10% DMSO to the PCR mix. The cycling con-
ditions were 98 °C for 2 min, followed by 35 cycles of
98 °C for 10 s, 64 °C for 5 s, 68 °C for 5 s, and 72 °C for
30 s. We cloned PCR products into the pJET1.2 vector
(Thermo Fisher), followed by Sanger sequencing of ~ 10
clones for each product.
Analysis of liver damage markers
After blood collection by tail vein puncture, serum coag-
ulated naturally at room temperature for 1 h. Samples
were then centrifuged at 2000×g for 20 min at 25 °C.
The serum fraction was removed, transferred to a new
tube, and immediately stored at − 80 °C. Serum samples
were thawed quickly at 37 °C immediately before meas-
uring. We used diagnostic assay kits (Beckman Coulter,
Inc. Teco Diagnostics) to determine alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), biliru-
bin, and total albumin (Alb) levels in the serum.
Tail-clip challenge assay
The phenotypic correction of hemophilia was assessed
by the tail clip survival test as previously described [51].
The tails of anesthetized HA mice were clipped at a
diameter of 1.5 mm, without subsequent cauterization.
After the procedure, we checked the mice every 4–8 h.
Clot formation and survival beyond 24 h were used to
indicate the correction of the murine hemophilia A
phenotype.
On-target and off-target analyses by deep sequencing
Genomic DNA from mouse livers and other organs was
isolated using the DNeasy Blood & Tissue Kit (Qiagen).
DNA samples from treated and untreated hemophilia
mice were utilized for on-target and off-target analyses.
The top 20 putative off-target sites of sgAlb were pre-
dicted using the COSMID Tool (http://crispr.bme.gatech.
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edu). Primers were designed using Primer3Plus to amplify
fragments of 240–285 bp surrounding the on-target and
off-target sequences (Additional file 1: Tables S6 and S7).
The target sequences were amplified with KAPA HiFi
DNA polymerase. The PCR cycling conditions were 98 °C
for 2min, followed by 30 cycles of 98 °C for 5 s, 64 °C for
10 s, and 72 °C for 5 s. All the amplicons from the same
sample were mixed for 150 bp paired-end sequencing on
the Illumina HiSeq X Ten (Novogene Co., Ltd). The out-
puts were analyzed using our optimized pipeline. Briefly,
high-quality reads (Q score > 30) were uploaded to the Gal-
axy platform (https://usegalaxy.org/) [52]. After processing
with fast length adjustment of short reads (FLASH) and
Barcode Splitter, the demultiplexed data were analyzed
using Cas-Analyzer (http://www.rgenome.net/cas-analyzer/
#!) [53]. The analyzed data were transferred to MS Excel
files, trimmed, and further processed using Visual Basic
for Applications (VBA). For clarity, we only listed the
top 10 indel patterns. For original Illumina sequen-
cing data, please contact the corresponding authors.
Multiphoton imaging and 3D reconstruction of edited
liver tissue
At 3 weeks or 1 year after hydrodynamic injection of
editing plasmid, we injected hemophilia A mice with
50 μl of APC-conjugated VE-cadherin antibody (APC
anti-mouse CD144; Biolegend) through the tail vein.
Mice were euthanized to harvest the liver tissue 5 min
later. Small pieces from different liver lobes were imme-
diately fixed in ice-cold 4% paraformaldehyde solution
for 6–8 h. The liver pieces were then washed with PBS,
immersed in 30% sucrose overnight, frozen in optimal
cutting temperature (OCT) compound (TissueTek), and
stored at − 80 °C. We generated 600–700-μm-thick sec-
tions using a CM1850 Cryostat (Leica) at − 20 °C. For
staining, sectioned chunks were re-hydrated in PBS, the
nuclei were labeled with DAPI for 10 min at room
temperature, then the section was mounted on a cham-
ber slide for imaging. High-resolution images were taken
using the Olympus FV1200MPE multiphoton laser scan-
ning microscope equipped with a water immersion lens
(× 20, N.A. = 1.05). A high-precision motorized stage was
used to collect the large-scale 3D mosaics using 405 nm,
561 nm, and 640 nm solid-state lasers. The boundaries
(in x, y, and z) of the tissue section were defined using
the Multi-Area Time Lapse function of the ASW micro-
scope operating-software provided by Olympus. The
software automatically generated a list of 3D stage posi-
tions covering the volume of interest. Individual image
tiles were 512 × 512 with a pixel dimension of 0.62 μm,
with an overlap between two adjacent images (x–y) be-
ing 10% and each z stack acquired in 2-μm steps (about
200 μm depth in total). Images were processed and 3D-
reconstructed using the Imaris software (Bitplane).
Statistical analysis
We used GraphPad Prism 7.0 (GraphPad Software, San
Diego, CA) for the preparation of figures and statistical
analysis. The mean ± SEM was determined for each
treatment group in the individual experiments. We used
two-tailed Welch’s paired t test or Welch’s unpaired t
test to determine the significances between the treat-
ment and control groups. A comparison among multiple
groups was analyzed by one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test.
A P value < 0.05 was considered significant.
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